Bausch Health Companies Inc. filed its third quarter 2026 earnings release on October 28, 2026, reporting consolidated revenues of $2.94 billion and raising its full year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted Cash Flows from Operations.

Key Highlights

  • Revenue up 10%: Total consolidated reported revenues were $2.94 billion for Q3 2026, compared with $2.68 billion in Q3 2025, an increase of $260 million.
  • GAAP net income: Consolidated net income attributable to Bausch Health was $436 million for Q3 2026, up from $179 million in Q3 2025.
  • Adjusted EBITDA surges 32%: Consolidated Adjusted EBITDA attributable to Bausch Health was $1,305 million for Q3 2026, compared with $986 million in Q3 2025.
  • Diluted EPS growth: GAAP diluted earnings per share attributable to Bausch Health was $1.15 in Q3 2026, versus $0.48 in Q3 2025; Adjusted EPS was $1.77, up from $1.16, an increase of 53%.
  • Cash position strengthened: Consolidated cash and cash equivalents were $2,485 million as of September 30, 2026, up from $1,309 million as of December 31, 2025.
  • Share repurchase authorized: The Board of Directors authorized a $50 million share repurchase program, primarily to offset dilution from anticipated vesting of management equity awards in 2027.
  • Guidance raised: Full year 2026 consolidated revenue guidance updated to $10.975 billion to $11.175 billion, with Adjusted EBITDA guidance of $4.315 billion to $4.415 billion.

Bausch Health Q3 2026 Segment and Financial Results Detail

According to the filing, Bausch Health (NYSE:BHC) reported total consolidated revenues of $2.94 billion for the three months ended September 30, 2026, a 10% increase on a reported basis and 8% on an organic basis over the prior year period. The company disclosed that the net impact of foreign exchange was de minimis in the quarter, and that excluding the impact of acquisitions of $37 million and divestitures and discontinuations of $11 million, revenue grew 8% organically.

At the segment level, the filing reported that the Salix segment led growth with revenues of $831 million, up 16% reported and 14% organically, with Xifaxan cited as the primary contributor at 16% revenue growth in the quarter. The Solta Medical segment reported revenues of $165 million, up 18% on a reported basis, though organic revenue declined 4%, reflecting the Asia Pacific region decreasing modestly. The Bausch + Lomb segment contributed $1,375 million in revenues, up 7% reported and 7% organically. The Diversified segment reported revenues of $271 million, up 5%, driven by what the company described as double-digit growth in Dermatology.

Consolidated operating income was $983 million for Q3 2026, compared with $619 million for Q3 2025, an increase of $364 million, according to the filing. The company generated $813 million of cash from operating activities in the quarter, an increase of 101% versus $405 million in Q3 2025. The filing also noted that Bausch Health, excluding Bausch + Lomb, delivered its fourteenth consecutive quarter of year-over-year revenue and Adjusted EBITDA growth, and that quarterly Adjusted EBITDA excluding Bausch + Lomb exceeded $1 billion for the first time. The company stated that more than $500 million of net debt reduction was achieved during the quarter. The filing contains forward-looking statements, including guidance figures, which are the company's own and subject to its cautionary language.

What Was Disclosed

Bausch Health disclosed Q3 2026 consolidated revenues of $2.94 billion, GAAP net income attributable to Bausch Health of $436 million, Adjusted EBITDA of $1,305 million, a $50 million share repurchase authorization, and raised full year 2026 revenue guidance to $10.975 billion to $11.175 billion.